<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559519</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000931-20</org_study_id>
    <nct_id>NCT01559519</nct_id>
  </id_info>
  <brief_title>Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy</brief_title>
  <official_title>Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of albumin infusion to prevent post
      tips hepatic encephalopathy'
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The outcome is the prevention of post tips hepatic encephalopathy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>one or more episodes of hepatic encephalopathy (&gt; grade 2 according to West Heven criteria)after TIPS placement</measure>
    <time_frame>one month post tips</time_frame>
    <description>evaluate the efficacy of albumin infusion to prevent the occurrence of hepatic encephalopathy (&gt; grade 2 according to West Heven criteria)one months after tips placement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial blood pressure &gt;120/80 mmHg and natremia &gt;130 mg/dl in cirrhotic patients one month after TIPS placement</measure>
    <time_frame>one month after tips placement</time_frame>
    <description>improving the hypovolemia, evaluated by the arterial blood pressure value, and hyponatremia (&lt;130 mg/dl)after albumine infusion for one month after tips placement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cirrhotic patients who underwent tips placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.</description>
    <arm_group_label>albumin</arm_group_label>
    <other_name>human albumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhotic patients

          -  TIPS placement

          -  Absence of Hepatic Encephalopathy at the enrolement

          -  Age &gt; 18 years

          -  No pregnancy

        Exclusion Criteria:

          -  Non-cirrhotic portal hypertension

          -  Previous liver transplantation

          -  Impossibility to attend the scheduled follow-up including the weekly visit as
             outpatients during the first month after TIPS (see the description of follow-up below)

          -  Sings of overt hepatic encephalopathy as well as a history of persistent HE at entry.
             The latter as a contraindication for TIPS placement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>oliviero riggio, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Prof oliviero Riggio</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>TIPS</keyword>
  <keyword>albumin</keyword>
  <keyword>hepatic encephalopathy</keyword>
  <keyword>hyponatremia</keyword>
  <keyword>hypovolemia</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

